A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study)
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Esmethadone (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms RELIANCE I
- Sponsors Relmada Therapeutics
Most Recent Events
- 18 Jun 2024 According to a Relmada Therapeutics Media Release, REL-1017 clinical data from the Reliance I Study were published in The Journal of Clinical Psychiatry.
- 18 Jun 2024 Results presented in a Relmada Therapeutics Media Release
- 20 Sep 2023 Results presented in a Relmada Therapeutics media release.